{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:17:38Z","timestamp":1760955458372},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T00:00:00Z","timestamp":1389312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0083658","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T16:32:12Z","timestamp":1389371532000},"page":"e83658","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Utilization and Comparative Effectiveness of Caspofungin and Voriconazole Early after Market Approval in the U.S"],"prefix":"10.1371","volume":"9","author":[{"given":"Sibel","family":"Ascioglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Arnold","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/infdis\/120.4.427","article-title":"A pharmacologic guide to the clinical use of amphotericin B","volume":"120","author":"DD Bindschadler","year":"1969","journal-title":"J Infect Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","article-title":"Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group","volume":"79","author":"TF Patterson","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1002\/cncr.24507","article-title":"Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001\u20132007): stable incidence but changing epidemiology of a still frequently lethal infection","volume":"115","author":"NV Sipsas","year":"2009","journal-title":"Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ijantimicag.2006.03.019","article-title":"Caspofungin: an advanced treatment approach for suspected or confirmed invasive aspergillosis","volume":"27","author":"J Maertens","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"ref5","article-title":"Decisions about voriconazole versus liposomal amphotericin B","volume":"346","author":"TJ Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"ref6","unstructured":"Cancidas approval history. Drugs @ FDA Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist\" xlink:type=\"simple\">http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist<\/ext-link>. Accessed: 10 Oct, 2013."},{"key":"ref7","unstructured":"Vfend approved history. Drugs @ FDA Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist\" xlink:type=\"simple\">http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist<\/ext-link>. Accessed: 10 Oct 2013"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1086\/320876","article-title":"Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses","volume":"33","author":"JH Rex","year":"2001","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1001\/archinternmed.2009.314","article-title":"Going off-label without venturing off-course: evidence and ethical off-label prescribing","volume":"169","author":"EA Largent","year":"2009","journal-title":"Arch Intern Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1056\/NEJMe078078","article-title":"Echinocandins\u2013first-choice or first-line therapy for invasive candidiasis?","volume":"356","author":"JD Sobel","year":"2007","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1542\/peds.2005-2183","article-title":"Fluconazole for the prevention of fungal infections: get ready, get set, caution","volume":"117","author":"AA Fanaroff","year":"2006","journal-title":"Pediatrics"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jac\/dkh348","article-title":"A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998\u20131999","volume":"54","author":"O Lortholary","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jac\/37.1.175","article-title":"An audit of the use of antifungal agents","volume":"37","author":"F Gutierrez","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/106002809402800219","article-title":"Use of antifungal therapy in hospitalized patients. I. Results prior to the marketing of fluconazole","volume":"28","author":"TH Grasela","year":"1994","journal-title":"Ann Pharmacother"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6904-5-1","article-title":"Hospital use of systemic antifungal drugs","volume":"5","author":"K de With","year":"2005","journal-title":"BMC Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/INF.0b013e31817eeee5","article-title":"Pediatric antifungal utilization: new drugs, new trends","volume":"27","author":"PA Prasad","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1056\/NEJMoa0707571","article-title":"Aprotinin during coronary-artery bypass grafting and risk of death","volume":"358","author":"S Schneeweiss","year":"2008","journal-title":"N Engl J Med"},{"key":"ref18","unstructured":"Averill R, Goldfield N, Hughes J, Muldoon J, Gay J, <etal>et al<\/etal>.. (2003) What Are APR-DRGs? An Introduction to Severity of Illness and Risk of Mortality Adjustment Methodology. Salt Lake City, UT: 3M Health Information Systems."},{"key":"ref19","unstructured":"Wynn BO, Beckett M, Hillborne L, Scott M, Bahney B (2007) Evaluation of Severity-Adjusted DRG Systems: Interim Report. RAND Health working paper series Prepared For the Centers for Medicare and Medicaid Services."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.clpt.6100249","article-title":"Developments in post-marketing comparative effectiveness research","volume":"82","author":"S Schneeweiss","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/aje\/kwj047","article-title":"Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect","volume":"163","author":"T Kurth","year":"2006","journal-title":"Am J Epidemiol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"P Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/pds.1062","article-title":"An application of propensity score matching using claims data","volume":"14","author":"JD Seeger","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref24","article-title":"The role of the c-statistic in variable selection for propensity score models","author":"D Westreich","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/01.EDE.0000081989.82616.7d","article-title":"Marginal structural models as a tool for standardization","volume":"14","author":"T Sato","year":"2003","journal-title":"Epidemiology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","article-title":"Off-label prescribing among office-based physicians","volume":"166","author":"DC Radley","year":"2006","journal-title":"Arch Intern Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"TJ Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/archinte.165.2.171","article-title":"National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation","volume":"165","author":"C Dai","year":"2005","journal-title":"Arch Intern Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.289.15.1969","article-title":"Disseminating innovations in health care","volume":"289","author":"DM Berwick","year":"2003","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJMp0802107","article-title":"Regulating off-label drug use\u2013rethinking the role of the FDA","volume":"358","author":"RS Stafford","year":"2008","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"J Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"TJ Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"R Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1086\/317487","article-title":"Burden of aspergillosis-related hospitalizations in the United States","volume":"31","author":"EJ Dasbach","year":"2000","journal-title":"Clin Infect Dis"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0083658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T20:03:57Z","timestamp":1540325037000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0083658"}},"subtitle":[],"editor":[{"given":"Joy","family":"Sturtevant","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,1,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0083658","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,10]]}}}